01:08:06 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2024-05-30 08:51:00

Copenhagen, Denmark, 30 May 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 March 2024. The Q1 report is available as an attached document to this press release and on FluoGuide’s website.

FluoGuide had no revenue for the period and posted a net loss of DKK 7,521 thousand (DKK 9,535 thousand) for the period 1 January to 31 March 2024. The financial result for the period is in line with the Company's development plans.

The total number of shares as of March 31, 2024, amounted to 12,208,384 shares. The total number of shares as of March 31, 2023, amounted to 11,814,500 shares. The average number of shares in Q1 2024 amounted to 12,208,384 shares.

KEY FIGURESQ1 24Q1 23YTD 2024YTD 20232023
DKK thousand1-Jan-241-Jan-231-Jan-241-Jan-231-Jan-23
 31-Mar-2431-Mar-2331-Mar-2431-Mar-2331-Dec-23
Net Revenue-----
Income before interest and tax (EBIT)-8,345-11,645-8,345-11,645-43,924
Net result for the period-7,521-9,535-7,521-9,535-38,377
Cash and bank10,68316,26910,68316,26921,668
      
Solvency ratio (%) 29%82%29%82%43%
Result per share (DKK)-0.62-0.81-0.62-0.81-3.22

 
HIGHLIGHTS DURING Q1:

  • FluoGuide provides strategic update and outlines development plans towards commercialization of FG001
  • FluoGuide enters collaboration within robot assisted head & neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company
  • Two new board members, Donna Haire (regulatory profile) and Roger Gunnarsson (financial profile)

HIGHLIGHTS AFTER Q1

  • FluoGuide selects laser system for photothermal cancer therapy with FG001

“FluoGuide published a collaboration with Intuitive Surgical in head & neck surgery which on top of the three positive clinical study phase II results published last year supports our long-term objective of improving the outcome for patients with cancer.” says Morten Albrechtsen, CEO at FluoGuide.

For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
+45 24 25 62 66,
ma@fluoguide.com

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB

About FluoGuide
FluoGuide is a biotech company specializing in precision cancer surgery. FluoGuide's lead product, FG001, is designed to enhance surgical accuracy by illuminating cancer cells intraoperatively using fluorescent light, which binds to the uPAR receptor, widely expressed in most solid cancer types. It is anticipated that FG001 will decrease both the incidence of local recurrence after surgery and surgical complications, improving cancer treatment and outcomes for patients, while also reducing healthcare costs. Moreover, FluoGuide’s technology platform may also be utilized for photothermal therapy (PTT), which kills cancer cells through heating them with the use of near-infrared light. A technique that spares healthy surrounding tissue from damage, offering a direct therapeutic effect of FG001, further benefiting patients undergoing cancer surgery.

FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO." For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com